探讨吉法酯片预防急性冠状动脉综合征后上消化道出血的疗效

目的比较吉法酯片观察组与对照组预防急性冠状动脉综合征后上消化道出血的疗效。方法将2008年至2010年住院的急性冠状动脉综合征患者100例纳入本组研究,其中男52例,女48例,年龄48～80岁,平均(72±11)岁,随机分为吉法酯片观察组(n=55)和对照组(n=45)。急性冠状动脉综合征常规治疗的方法相同。观察两组并发上消化道出血的发生率。结果两组急性冠状动脉综合征后上消化道出血的发生率分别为:观察组3.6%,对照组11.1%。两组比较差异有统计学意义(P<0.05)。结论急性冠状动脉综合征患者应用胃黏膜保护剂吉法酯预防上消化道出血有较好效果。

Clinical Observation on Prevention of Upper Gastrointestinal Bleeding after Acute Coronary Syndrome by Gefarnate Tablet

Objective To study the prevention of upper gastrointestinal bleeding after acute coronary syndrome（ACS）.Method The 2008-2010 hospitalization of 100 patients with ACS included in this group of researchers,including 52 males and 48 females,aged 48 to 80 years,mean（72±11） years of age,were randomly divided into Gefarnate tablet observation group（n= 55） and the control group（n=45）.Conventional treatment of ACS the same way.Upper gastrointestinal bleeding were observed incidence.Results Two groups ACS patents the incidence of upper gastrointestinal bleeding were： study group 3.6%,control group 11.1%.The difference was statistically significant（P〈0.05）.Conclusion ACS patients with gastric mucosal protective agents to prevent Kyrgyz law ester upper gastrointestinal bleeding have better results.